BCDA Stock — BioCardia Inc.: Cash, EV, Pipeline

Share price

$1.17

Market cap

$17.7M

Cash

$4.1M

Enterprise value

$13.6M

Balance sheet

Cash	$4.1M
Debt	$0.0M
Net cash	$4.1M
Enterprise value	$13.6M
Basic shares	15.0M shares
Fully diluted shares	23.8M shares
Fully diluted market cap	$27.9M
Cash per share	$0.27

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BCDA daily closes…

Loading price history…

Pipeline assets

CardiAMP Cell Therapy System

Phase 3 · Active Modality: autologous mononuclear cell therapy (device-led combination product)

Partnerships CART-Tech B.V.: Heart3D development/license/distribution partner (BioCardia holds exclusive biotherapeutic-delivery licenses and distribution rights worldwide; cardiac biopsy rights in US)

Indications

Ischemic heart failure with reduced ejection fraction (HFrEF) (Phase 3)
Chronic myocardial ischemia with refractory angina (Phase 3)

Status note Confirmatory CardiAMP HF II trial enrolling. May 2026 PMDA Consultation Record supports a Japan approval submission based on three completed trials. FDA Q-Sub (June 2026) confirms ongoing HF II may support PMA. Breakthrough Device Designation January 2022.

CardiALLO

Phase 2 · Active Modality: allogeneic mesenchymal stem cell (MSC) therapy

Aliases BCDA-03

Indications

Ischemic inflammatory HFrEF (Phase 2)

Status note IND approved; 3+3 roll-in dose-escalation plus 360-patient randomized controlled study per IND amendment; low-dose (20M cells) cohort completed, DSMB recommended proceeding. Seeking non-dilutive/partnering funding.

PulmALLO

Phase 2 · Active Modality: allogeneic mesenchymal stem cell (MSC) therapy

Aliases BCDA-04

Indications

Acute respiratory distress syndrome (ARDS) (Phase 2)

Status note IND approved 2022 for ARDS caused by COVID-19; not yet advanced into clinic; seeking partnering; no milestones set for 2026.

Helix biotherapeutic delivery system

Stage not disclosed · Active Modality: transendocardial delivery catheter system

Partnerships Selectively partnered for biotherapeutic delivery with revenue sharing; CART-Tech B.V. (Heart3D imaging enhancement)

Indications

Intramyocardial therapeutic/diagnostic agent delivery (Stage not disclosed)

Status note FDA pre-submission under Q-Submission program; May 2026 meeting agreed two pathways to marketing clearance, preferred route simultaneous with CardiAMP HF approval, with a follow-on DeNovo option. Safety data from 15 clinical trials.

Morph DNA steerable introducers

Approved · Active Modality: steerable introducer catheter

Aliases AVANCE

Indications

Cardiac/vascular access procedures (Approved)

Status note FDA market clearance received (8 French equivalent for transseptal cardiac procedures under name AVANCE; Morph-DNA family cleared across diameters/lengths); generates modest product revenue.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem
Lead indication	Heart Failure, Systolic
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05925608	Phase 2	Active, not recruiting	Sponsor	BCDA	—	Heart Failure, Systolic	—
NCT06258447	Not disclosed	Recruiting	Sponsor	BCDA	—	Ischemic Heart Failure	—
NCT03455725	Not disclosed	Active, not recruiting	Sponsor	BCDA	—	Refractory Angina; Chronic Myocardial Ischemia	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for BioCardia, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BCDA — BioCardia Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials